Emergency & Toxicology

SSRI overdose and serotonin syndrome

Clinical Overview and When to Suspect SSRI Overdose and Serotonin Syndrome

— Citalopram/escitalopram: dose-dependent QTc prolongation and seizures (citalopram >40 mg/day or large overdose)

— Co-ingestion with another serotonergic agent → tips patient into SS

— SSRI/SNRI + MAOI (including linezolid, methylene blue, selegiline) — the classic boards trigger

— SSRI + tramadol, meperidine, fentanyl, dextromethorphan

— SSRI + triptans, ondansetron, metoclopramide

— SSRI + St. John's wort, MDMA, cocaine, LSD

— Recent dose increase or addition of a CYP inhibitor (fluoxetine + tramadol)

— Patient on antidepressant + new drug/dose change + altered mental status, tremor, or hyperthermia

— "Flu-like" agitated patient post-overdose with clonus (especially inducible or spontaneous lower extremity clonus)

— Postoperative patient on chronic SSRI given fentanyl/meperidine who becomes hyperthermic and rigid

Board pearl: The triad to anchor on is (1) mental status change, (2) autonomic hyperactivity, (3) neuromuscular hyperactivity — particularly clonus and hyperreflexia, lower > upper extremity. Clonus is the most specific finding and distinguishes SS from neuroleptic malignant syndrome (NMS), where rigidity dominates and reflexes are suppressed. Always ask about timing of last medication change — SS within hours, NMS over days to weeks.

Serotonin syndrome (SS) is a clinical toxidrome caused by excess serotonergic activity at central and peripheral 5-HT receptors, classically 5-HT2A. It exists on a spectrum from mild tremor/anxiety to life-threatening hyperthermia, rigidity, and rhabdomyolysis.

SSRI overdose alone is usually benign — isolated ingestion of sertraline, fluoxetine, escitalopram, or citalopram rarely produces life-threatening toxicity. Two major exceptions:

Common precipitants of SS (high-yield combos):

Onset is rapid: 60% within 6 hours of the inciting change. This timing is the single most useful historical clue.

When to suspect SS in the ED:

Presentation Patterns and Key History

— Mental status: anxiety, agitation, restlessness, delirium, in severe cases coma

— Autonomic instability: diaphoresis, tachycardia, mydriasis, hypertension or labile BP, hyperthermia, flushing, diarrhea, bowel hyperactivity

— Neuromuscular excitation: tremor, hyperreflexia, clonus (spontaneous, inducible, or ocular), myoclonus, muscle rigidity (late/severe), shivering

— Mild: afebrile, tachycardia, mydriasis, diaphoresis, intermittent tremor or hyperreflexia. Often outpatient-recognizable.

— Moderate: T 38–40°C, hyperactive bowel sounds, sustained clonus, agitation, pressured speech

— Severe: T >41.1°C, severe hypertension/tachycardia → shock, muscular rigidity (especially truncal), rhabdomyolysis, DIC, ARDS, multiorgan failure

— Full medication reconciliation including OTC (dextromethorphan-containing cold remedies), supplements (St. John's wort, SAM-e, tryptophan, ginseng), illicit drugs (MDMA, cocaine, LSD)

— Recent prescription changes: new SSRI, dose escalation, addition of tramadol/triptan/linezolid, switching antidepressants without adequate washout

— Fluoxetine washout must be ≥5 weeks before starting an MAOI due to long half-life of norfluoxetine

— Intentional overdose? Quantity, time, co-ingestants (acetaminophen, alcohol, benzodiazepines)

— Psychiatric history, suicidality, prior overdoses

— SS: minutes to hours after the inciting agent

— Most cases resolve within 24 hours once offending agents are stopped — long resolution should make you reconsider the diagnosis

Step 3 management: In the ED, your first three orders for a suspected SS patient should be (1) stop all serotonergic agents — verify with pharmacy and reconciliation, (2) place on continuous cardiac monitoring with core temperature, and (3) obtain IV access, labs, and ECG. Documenting the timeline of the last serotonergic exposure is both diagnostic and medicolegally protective.

Three core domains (Hunter/Sternbach framework):

Severity spectrum:

Key history to elicit (CCS-style):

Timing clues:

Physical Exam Findings and Hemodynamic Assessment

— Tachycardia (often >120), hypertension, tachypnea

— Hyperthermia is the cardinal danger sign — T >38.5°C predicts ICU course; T >41.1°C is life-threatening and demands aggressive cooling and paralysis

— Hypotension may occur in late shock or with MAOI co-toxicity

— Inducible clonus: dorsiflex ankle rapidly — sustained rhythmic beats = positive

— Spontaneous clonus: pathognomonic when combined with serotonergic exposure

— Ocular clonus: slow horizontal eye movements

— Hyperreflexia and clonus are greater in the lower extremities than upper — a near-unique feature

— Rigidity, when present, is also lower-extremity predominant and is a late/severe finding

— Continuous telemetry; arterial line if severe

— Foley to measure urine output (rhabdo risk)

— Core (rectal or bladder) temperature, not axillary — peripheral readings underestimate

Key distinction: Compare the four hyperthermic toxidromes —

— Serotonin syndrome: clonus, hyperreflexia, hyperactive bowel, rapid onset

— NMS: "lead-pipe" rigidity, hyporeflexia, bradykinesia, slow onset days–weeks, dopamine antagonist exposure

— Anticholinergic: dry skin, absent bowel sounds, urinary retention, "mad as a hatter"

— Sympathomimetic: diaphoresis, agitation, normal reflexes, no clonus

Board pearl: The most reliable single bedside maneuver is checking ankle clonus. Sustained inducible or spontaneous clonus in a patient on serotonergic medication = SS until proven otherwise.

Vital signs drive triage:

Neuromuscular exam (most diagnostic):

Mental status: agitation > somnolence early; coma in severe cases

Pupils: mydriasis (sympathomimetic-like)

Bowel sounds: hyperactive — distinguishes from anticholinergic toxidrome (silent bowel) and NMS (normal/decreased)

Skin: diaphoretic, flushed — contrast with anticholinergic (dry, flushed) and NMS (diaphoretic but more bradykinetic)

Hemodynamic assessment:

Diagnostic Workup — Initial Labs, Imaging, ECG

— Spontaneous clonus

— Inducible clonus + agitation or diaphoresis

— Ocular clonus + agitation or diaphoresis

— Tremor + hyperreflexia

— Hypertonia + T >38°C + ocular or inducible clonus

— CBC, CMP (electrolytes, BUN/Cr, LFTs, glucose)

— CK (rhabdomyolysis screen; trend q6h if elevated)

— Lactate, venous blood gas

— Coags (PT/INR, PTT) and fibrinogen if severe — DIC risk

— UA with myoglobin

— Acetaminophen and salicylate levels — mandatory in any intentional overdose

— Urine pregnancy test in women of reproductive age

— Ethanol level

— Urine drug screen (limited utility but documents co-ingestion)

— Citalopram overdose: dose-dependent QTc prolongation, can cause torsades. >40 mg/day or large ingestion → cardiac monitoring 12–24 hours

— Escitalopram: less but still relevant QTc effect

— Other SSRIs: minimal QT effect

— Look for QRS widening (suggests TCA or bupropion co-ingestion, not SSRI)

— CT head if altered mental status without clear toxicologic explanation, to exclude hemorrhage/structural cause

— CXR if hypoxia, aspiration concern, or ARDS suspicion

Step 3 management: Always order acetaminophen and salicylate levels plus pregnancy test in any intentional overdose — this is a recurring Step 3 testing point because missed APAP toxicity has a 72-hour silent window and changes the entire treatment plan.

Serotonin syndrome is a clinical diagnosis — there is no confirmatory lab. Apply the Hunter Criteria (most sensitive/specific): serotonergic agent exposure plus one of:

Sternbach criteria are also acceptable but less specific.

Initial labs (all overdose/SS workups):

ECG is critical:

Imaging:

Activated charcoal (1 g/kg) only within 1–2 hours of ingestion and only if airway is protected — rarely indicated in SS itself, sometimes for large recent SSRI overdose

Diagnostic Workup — Advanced or Confirmatory Studies

— QTc <500 ms and stable

— Asymptomatic ≥12–24 hours post-ingestion

— Wide QRS → suspect TCA, bupropion, diphenhydramine co-ingestion

— Persistent acidosis → consider salicylate, metformin, methanol/ethylene glycol

— Anion gap with osmolar gap → toxic alcohols

CCS pearl: On a CCS simulation, after stabilizing a serotonin syndrome patient, advance the clock in 2-hour blocks to reassess vitals, mental status, CK, and QTc. Do not discharge or transfer until: temperature normal ≥6 hours, clonus resolved, CK trending down, QTc normal, psychiatric clearance documented. Premature discharge before psychiatric assessment is a common CCS pitfall that loses points and mirrors real medicolegal liability.

There is no serum serotonin level of clinical use. Diagnosis remains clinical via Hunter criteria.

Repeat ECG and QTc monitoring every 2–4 hours for citalopram/escitalopram overdose until QTc normalizes. Discharge from cardiac monitoring requires:

CK trending (q6h) if initial >1000 or symptoms severe; rhabdomyolysis defined as CK >5× ULN or >1000 U/L. Monitor for AKI.

DIC panel in severe SS: PT, PTT, fibrinogen, D-dimer, platelets, smear for schistocytes

LP if febrile altered mental status and meningitis/encephalitis cannot be excluded — diagnostic uncertainty is common when history of serotonergic exposure isn't clear

EEG if persistent altered mental status without explanation (subclinical status epilepticus)

TSH if presentation overlaps with thyroid storm

Toxicology consult / Poison Control (1-800-222-1222): low threshold; documenting consultation supports management decisions and is medicolegally protective

Psychiatric evaluation for all intentional overdoses prior to discharge — required regardless of medical clearance status

Distinguishing co-toxicities:

Risk Stratification and First-Line Management Logic

— Mild SS (afebrile, tachycardia, tremor, hyperreflexia): supportive care + benzodiazepines + observation 6–12 hours in ED

— Moderate SS (T 38–40°C, sustained clonus, agitation): aggressive benzodiazepines, IV fluids, active cooling, admit to step-down or ICU

— Severe SS (T >41.1°C, rigidity, autonomic instability, AMS): ICU, intubation with non-depolarizing paralysis, aggressive cooling, consider cyproheptadine

— Discontinue all serotonergic agents — verify medication reconciliation

— IV crystalloid for volume support and rhabdo prevention (target UOP 1–2 mL/kg/hr)

— Active external cooling: ice packs, cooling blankets, evaporative cooling. Antipyretics (acetaminophen) do not work — hyperthermia is from muscle activity, not hypothalamic set point

— Benzodiazepines (lorazepam 1–2 mg IV or diazepam 5–10 mg IV, titrate) — cornerstone for agitation, tremor, autonomic hyperactivity, and to reduce muscular hyperactivity

— Cardiac monitoring and serial vitals q15min initially

— Physical restraints alone — promote isometric muscle contraction → worsen hyperthermia and rhabdo. Always pair with chemical sedation.

— Antipyretics — no benefit

— Bromocriptine, dantrolene — these are for NMS, not SS (dantrolene has been used in severe SS but is not first line)

— Succinylcholine if intubating with severe rhabdo/hyperkalemia — use rocuronium

Step 3 management: The single most effective first-line intervention after stopping the offending drug is aggressive benzodiazepine sedation. Titrate to calm, not unconscious. Benzodiazepines treat agitation, reduce muscle activity (lowering temperature), blunt autonomic surge, and prevent seizures — they hit four problems with one drug class. This is testable.

Stratify severity at presentation — this drives disposition and therapy intensity:

Universal first-line measures (apply to all):

Avoid:

Pharmacotherapy — First-Line Drug Regimen

— Lorazepam 1–2 mg IV q10–15 min PRN, or diazepam 5–10 mg IV q10–15 min PRN

— No ceiling dose; titrate to resolution of agitation, tremor, and to RR/HR control

— Total doses of 30–60 mg diazepam-equivalents in the first hour are common in moderate–severe cases

— 5-HT2A antagonist, the antidote of choice

— Loading dose 12 mg PO/NG, then 2 mg q2h until clinical response

— Maintenance 8 mg PO q6h

— Only available oral/NG — must have airway protected if obtunded

— Anticholinergic and sedating; expect sedation

— Mist + fan (evaporative), ice packs to groin/axillae, cooled IV fluids

— Endovascular cooling rarely needed

— Rapid sequence intubation with rocuronium (non-depolarizing, avoids succinylcholine in hyperkalemic rhabdo)

— Continuous paralysis with vecuronium/rocuronium drip eliminates muscular hyperthermia source

— Sedation with propofol or midazolam infusion

— Avoid succinylcholine (hyperkalemia from rhabdo)

— Short-acting agents preferred: esmolol or nitroprusside — autonomic swings can reverse

— Avoid long-acting beta-blockers (propranolol) — can mask shifts to hypotension

— Antipsychotics (olanzapine, haloperidol) — historical use, but they can worsen hyperthermia, lower seizure threshold, and confound NMS vs SS picture

— Bromocriptine, dantrolene (NMS therapy)

Board pearl: Cyproheptadine is the antidote, but benzodiazepines + cooling + supportive care resolve most cases. If the stem describes a severe agitated hyperthermic patient on SSRI + tramadol failing benzos, the next step is cyproheptadine 12 mg PO/NG.

Benzodiazepines (first line):

Cyproheptadine (second line, for moderate–severe SS not improving with benzodiazepines):

Active cooling: target core temp <38.5°C

Severe SS / T >41.1°C:

Hypertension/tachycardia management:

Avoid:

Procedures and Expanded Management for Severe Cases

— Indications for intubation: T >41°C unresponsive to cooling, severe agitation precluding cooling, AMS with airway compromise, refractory rigidity, respiratory failure

— RSI: rocuronium 1.2 mg/kg (preferred) + induction agent (etomidate or ketamine; propofol if hemodynamically tolerant)

— Avoid succinylcholine in rhabdo/hyperkalemia

— Post-intubation: continuous neuromuscular blockade until temperature controlled, then wean

— Aggressive crystalloid (LR or NS) — 2–4 L initial bolus, then maintenance targeting UOP 1–2 mL/kg/hr

— Hypotension: norepinephrine first line; avoid indirect sympathomimetics (dopamine, ephedrine) — unpredictable response with MAOI co-ingestion

— Hypertension: esmolol drip or nitroprusside; short-acting only

— Activated charcoal 1 g/kg PO/NG within 1–2 hours of large SSRI ingestion if airway protected

— Gastric lavage — not recommended routinely

— Hemodialysis — not effective for SSRIs (large Vd, high protein binding)

— IV fluids to UOP 1–2 mL/kg/hr

— Monitor K+, Ca2+, phosphate, CK q6h

— Bicarbonate for urinary alkalinization is controversial; not standard

— Dialysis if AKI with refractory hyperkalemia/acidosis

— Benzodiazepines first line

— Refractory: levetiracetam or phenobarbital

— Avoid phenytoin (limited efficacy in toxic seizures)

— Magnesium 2 g IV

— Correct K+ to 4.0+, Mg2+ to 2.0+

— Overdrive pacing if recurrent torsades

— Avoid QT-prolonging antiemetics (ondansetron — also serotonergic!)

Step 3 management: For nausea in SS, use metoclopramide cautiously or avoid; ondansetron is contraindicated (serotonergic and QT-prolonging). Consider promethazine or droperidol with caution, or simply benzodiazepines, which suppress nausea.

Airway and breathing (severe SS):

Circulation:

Decontamination:

Rhabdomyolysis management:

Seizure management:

Citalopram-specific torsades risk:

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher baseline polypharmacy → more drug interaction risk

— Common culprits: SSRI + tramadol (chronic pain), SSRI + linezolid (UTI/skin infection), SSRI + ondansetron (post-op nausea)

— Reduced hepatic clearance prolongs SSRI half-life; fluoxetine and its active metabolite norfluoxetine especially persistent

— Falls, delirium, and hyponatremia (SIADH from SSRI) complicate picture

— Lower benzodiazepine doses (start lorazepam 0.5 mg) to avoid oversedation, but do not undertreat severe SS — titrate to effect

— Consider SSRI-induced SIADH in any elderly patient with confusion + hyponatremia on a new SSRI; check Na+ at 2 weeks and 1 month after initiation

— SSRIs are primarily hepatically metabolized — modest renal dose adjustment

— Paroxetine and citalopram accumulate in CKD

— Rhabdomyolysis from SS more likely to cause AKI in CKD — aggressive fluids critical

— Linezolid (MAOI activity) dosed in renal failure; co-administration with SSRI is a frequent inpatient trigger of SS

— All SSRIs require dose reduction in cirrhosis (typically 50%)

— Sertraline preferred in liver disease (relatively safer profile)

— Avoid fluvoxamine in significant hepatic dysfunction

— Acetaminophen co-ingestion in chronic liver disease patients is doubly dangerous

— Beers Criteria flags SSRIs as potentially inappropriate in patients with falls/fractures and SIADH risk

— Tramadol + SSRI is a high-risk combination flagged on Beers; avoid

Board pearl: Linezolid is a reversible MAOI with often-forgotten serotonergic interaction. An elderly patient on chronic sertraline admitted for VRE/MRSA and started on linezolid who develops fever, tremor, and clonus — this is the classic Step 3 stem. Management: stop linezolid, supportive care, benzodiazepines; the SSRI is often continued depending on severity.

Elderly:

Renal impairment:

Hepatic impairment:

Frailty/dementia:

Special Populations — Pregnancy, Pediatrics, and Other Subgroups

— SSRIs are generally continued in pregnancy when benefit > risk; sertraline is the preferred agent (extensive safety data, low milk transfer)

— Paroxetine is avoided in first trimester (cardiac malformations, FDA Category D historically)

— Neonatal adaptation syndrome: transient irritability, tremor, feeding difficulty, hypoglycemia in newborns exposed in third trimester — usually self-limited; not a contraindication

— Persistent pulmonary hypertension of the newborn (PPHN): small absolute risk increase with late-pregnancy SSRI exposure

— In overdose during pregnancy: treat the mother — maternal stabilization is fetal stabilization. Continuous fetal monitoring if viable gestational age.

— Black box warning: increased suicidal ideation in patients <25 on SSRIs — fluoxetine and escitalopram are FDA-approved for pediatric depression; fluoxetine for ages ≥8

— Adolescent intentional overdose is common — full mental health evaluation mandatory

— Pediatric SS presents similarly but clonus may be harder to elicit; rely on hyperreflexia, agitation, and autonomic signs

— Weight-based dosing for benzodiazepines and cyproheptadine

— Postpartum depression treatment with sertraline is first line; SS risk is the same as nonpregnant patient

— Fluoxetine washout 5 weeks before MAOI

— Other SSRIs: 2 weeks washout before MAOI

— MAOI to SSRI: 2 weeks washout

— Failing to honor washouts is the most common iatrogenic cause of SS — this is the boards' favorite "what went wrong" scenario

Step 3 management: A 19-year-old presents with intentional ingestion of her sertraline plus dextromethorphan-containing cold syrup. After medical clearance, you must (1) obtain APAP/salicylate/pregnancy test, (2) psychiatric consultation before discharge, (3) involve family/safety contacts, and (4) ensure lethal means restriction counseling — removing/securing remaining medications at home.

Pregnancy:

Pediatrics/adolescents:

Postpartum:

Transitions between antidepressants:

Complications and Adverse Outcomes

— Rhabdomyolysis (CK >5× ULN) → AKI from myoglobin cast nephropathy

— Electrolyte derangements: hyperkalemia, hypocalcemia, hyperphosphatemia, hyperuricemia

— DIC in severe hyperthermia — schistocytes, thrombocytopenia, low fibrinogen, elevated D-dimer

— Hepatic injury (transaminitis, rarely fulminant)

— ARDS

— Acute hypoxic-ischemic encephalopathy with prolonged T >41°C

— Arrhythmias (especially with citalopram → torsades)

— Hypertensive emergency, then hypotensive shock as muscle injury and volume depletion progress

— Myocardial injury (demand ischemia, troponin elevation)

— Seizures (5–15% of severe cases)

— Persistent encephalopathy after rewarming

— Posterior reversible encephalopathy syndrome (PRES) — rare

— Succinylcholine-triggered hyperkalemic arrest in rhabdo patient

— Use of bromocriptine (worsens SS by adding serotonergic load)

— Physical restraints alone without sedation → worsened muscle activity, hyperthermia

— Antipsychotic administration confounding diagnosis or precipitating NMS overlap

— Recurrence if offending medication restarted without reconciliation

— Missed psychiatric needs → repeat overdose

— SSRI-induced SIADH (hyponatremia) developing in days post-discharge

— Sexual dysfunction, weight gain, GI side effects affecting medication adherence long-term

Key distinction: Hyperthermia in SS is generated by muscle activity, not central thermoregulation failure. Therefore, treatment must reduce muscle activity (benzodiazepines, paralysis) and provide external cooling — acetaminophen and NSAIDs do not work and may add hepatorenal injury. This is a classic Step 3 distractor answer.

Hyperthermia-related:

Cardiovascular:

Neurologic:

Death: rare in SSRI monotherapy overdose; mortality in severe SS ~2–12%, almost always from hyperthermia complications

Aspiration pneumonia during AMS

Iatrogenic complications:

Discharge complications:

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Discharge home (rare, mild cases only): asymptomatic ≥6 hours after exposure, normal vitals, no clonus, normal labs, no QTc prolongation, psychiatric clearance if intentional, reliable follow-up

— Observation/medical floor: mild SS resolving with benzodiazepines, no hyperthermia, normal CK, no ongoing autonomic instability — typically 24-hour observation

— Step-down/telemetry: moderate SS, citalopram overdose with QTc 470–500 ms, ongoing benzodiazepine requirement

— ICU: any of —

— T >40°C

— Sustained rigidity

— Need for intubation or continuous sedation infusion

— Hemodynamic instability (vasopressors or aggressive antihypertensive titration)

— Rhabdomyolysis with CK >5000 or AKI

— Seizures

— Arrhythmias, QTc >500 ms, torsades

— Need for cyproheptadine + close monitoring

— Medical toxicology or Poison Control (1-800-222-1222) — always for moderate–severe SS or any unclear toxidrome

— Psychiatry — mandatory for all intentional overdoses, ideally before discharge

— Nephrology if AKI requiring RRT

— Cardiology if QTc prolongation, torsades, or hemodynamic instability

— Social work for safety planning, lethal means restriction, outpatient follow-up coordination

— If your facility lacks ICU or toxicology capability and patient is severe, transfer after stabilization (airway secured, cooling initiated, benzodiazepines started)

— Document the timeline and SBAR handoff carefully

CCS pearl: On CCS, after a severe SS patient is intubated and stabilized in the ED, the correct next order set is: transfer to ICU, consult medical toxicology, consult psychiatry (when stable for evaluation), and order serial CK, BMP, ECG. Forgetting the psychiatry consult is the most common missed point on intentional-overdose cases.

ED disposition decisions:

Consults to obtain:

Inter-facility transfer:

Key Differentials — Same-Category (Other Toxidromes/Hyperthermic Syndromes)

— Onset: days to weeks (vs hours in SS)

— Trigger: dopamine antagonists (haloperidol, risperidone, antiemetics) or dopamine withdrawal (Parkinson's meds stopped)

— Exam: "lead-pipe" rigidity, bradykinesia, hyporeflexia, normal/decreased bowel sounds

— Labs: CK often massively elevated (>10,000), leukocytosis

— Treatment: stop offending agent, supportive care, bromocriptine, dantrolene, amantadine

— Trigger: volatile anesthetics or succinylcholine in genetically susceptible patient (ryanodine receptor mutation)

— Onset: minutes during anesthesia

— Exam: rigidity (including masseter), hypercarbia, acidosis, hyperthermia

— Treatment: dantrolene, stop trigger, cooling

— "Hot as a hare, dry as a bone, red as a beet, blind as a bat, mad as a hatter"

— Dry skin, absent bowel sounds, urinary retention, mydriasis, hallucinations

— Trigger: diphenhydramine, TCAs, atropine, jimson weed

— Treatment: supportive, benzodiazepines; physostigmine in select cases

— Trigger: cocaine, methamphetamine, MDMA, PCP

— Exam: diaphoresis, agitation, mydriasis, normal reflexes, no clonus

— Treatment: benzodiazepines, cooling; avoid beta-blockers (unopposed alpha)

— Trigger: thyrotoxicosis precipitated by infection, surgery, iodine load

— Exam: tachycardia (often AF), fever, agitation, goiter, ophthalmopathy

— Treatment: beta-blockers, PTU/methimazole, iodine, steroids

Key distinction: SS = hours after serotonergic drug + clonus + hyperreflexia + hyperactive bowel. NMS = days after antipsychotic + lead-pipe rigidity + hyporeflexia + normal/quiet bowel. Clonus is the single most discriminating finding between SS and NMS. Memorize this contrast — it appears repeatedly on boards.

Neuroleptic malignant syndrome (NMS):

Malignant hyperthermia (MH):

Anticholinergic toxidrome:

Sympathomimetic toxidrome:

Thyroid storm:

Key Differentials — Other-Category Causes

— Meningitis/encephalitis (especially viral or HSV) — fever + AMS + photophobia + nuchal rigidity

— LP with CSF analysis if any uncertainty; do not delay empiric antibiotics/antivirals

— Exertional or environmental hyperthermia without serotonergic drug exposure

— Dry skin in classic (non-exertional) heat stroke; diaphoretic in exertional

— No clonus; treatment is rapid cooling

— Hyperthermia from sustained motor activity

— EEG diagnostic

— Fever, tachycardia, AMS — but reflexes usually normal, no clonus, lactate elevation, infectious source

— Tremor, tachycardia, hypertension, diaphoresis, hyperreflexia possible

— History of cessation, no serotonergic drug exposure

— Treatment: benzodiazepines (overlap with SS treatment, but recognize the distinct etiology)

— Trismus, opisthotonos, generalized rigidity with maintained consciousness

— Recent wound, lack of immunization

— Rare; generalized muscle spasms with preserved sensorium, no clonus

— Glycine receptor antagonism

— Central fever, locked-in or coma

— Imaging diagnostic

Step 3 management: When the diagnosis of SS is uncertain and a patient is febrile with AMS, do not anchor. Order CT head, LP, blood cultures, and empiric ceftriaxone + vancomycin + acyclovir while you simultaneously stop serotonergic drugs and start benzodiazepines/cooling. The cost of treating possible meningitis empirically is far lower than missing it. Treat both possibilities until one is excluded.

CNS infection:

Heat stroke:

Status epilepticus / postictal state:

Sepsis with delirium:

Sympathomimetic intoxication (already covered) — overlaps significantly when MDMA causes both sympathomimetic and serotonergic effects

Alcohol or benzodiazepine withdrawal:

Tetanus:

Strychnine poisoning:

Hypothalamic stroke / pontine hemorrhage:

Secondary Prevention, Discharge Medications, and Long-Term Plan

— Provide written list of all serotonergic medications to avoid in combination with the patient's SSRI: tramadol, meperidine, dextromethorphan, triptans, MAOIs, linezolid, methylene blue, ondansetron, St. John's wort, MDMA

— Educate on OTC pitfalls — cough/cold preparations containing dextromethorphan

— Provide patient with a wallet card or after-visit summary listing their antidepressant and high-risk interactions

— After mild SS from a clear drug-drug interaction: SSRI can usually be resumed at prior dose once the offending second agent is removed

— After moderate–severe SS or intentional overdose: discuss with psychiatry; often resume at lower dose with closer follow-up

— After overdose: ensure limited-quantity prescribing (e.g., 2-week supply) and lethal means restriction

— Always honor washout periods: 2 weeks between most SSRIs and MAOIs; 5 weeks for fluoxetine to MAOI

— Avoid abrupt cross-tapers with serotonergic agents

— Pain management without tramadol/meperidine — use acetaminophen, NSAIDs (if no CKD/ulcer), or non-tramadol opioids (morphine, hydromorphone, oxycodone — minimal serotonergic activity)

— Migraine management: avoid triptans concurrent with SSRI? Recent FDA review concluded combined use is generally safe for most patients, but document risk-benefit discussion

— Outpatient psychiatry within 1 week for intentional overdose

— Primary care within 2 weeks

— Therapy referral (CBT, IPT) if not already established

Board pearl: Tramadol + SSRI is one of the most heavily tested combinations on Step 3 because both prescribers (often pain and psychiatry) may be unaware of the other's prescription. At discharge, perform deliberate medication reconciliation and educate the patient to mention their SSRI any time a new pain or cold medication is prescribed.

Medication reconciliation at discharge:

Resuming the SSRI?

Antidepressant transitions:

Comorbid disease management:

Mental health follow-up:

SIADH screen: check sodium at 2 weeks and 1 month after SSRI initiation, especially in elderly

Follow-Up, Monitoring Parameters, and Counseling

— Intentional overdose: psychiatry within 1 week, primary care within 1–2 weeks

— Unintentional SS from drug interaction: primary care within 1–2 weeks, psychiatry for SSRI management within 4 weeks

— Severe SS with ICU stay: post-ICU clinic follow-up if available; assess cognitive, functional, and psychiatric sequelae

— First post-discharge visit: BP, HR, weight, suicide risk assessment (PHQ-9, C-SSRS), medication adherence and side effects, alcohol/substance use screening

— Labs at 2 weeks: sodium (SIADH risk), especially in elderly

— At 4–6 weeks: PHQ-9 to assess SSRI efficacy; SSRIs require 4–6 weeks for full antidepressant effect

— Annual: weight, BP, lipid panel (some SSRIs associated with weight changes)

— Symptoms of serotonin syndrome to recognize: tremor, sweating, restlessness, fast heart rate, fever, muscle twitching → seek emergency care

— Discontinuation syndrome if SSRI stopped abruptly: "FINISH" — flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances, hyperarousal. Taper over 2–4 weeks.

— Bleeding risk with SSRIs (especially with NSAIDs, anticoagulants) — consider PPI in elderly on aspirin

— Sexual dysfunction is common; discuss proactively

— Suicidality monitoring — increased risk in first weeks, particularly <25 years old

— Post-severe SS: PT/OT if prolonged ICU stay or rhabdomyolysis-related weakness

— Cognitive assessment if persistent symptoms after hyperthermia

Step 3 management: SSRIs require 4–6 weeks at therapeutic dose before efficacy is judged. Do not switch agents prematurely. Consider dose escalation at 4 weeks if partial response; switch to a different SSRI or SNRI if no response by 6–8 weeks. Document PHQ-9 trends at each visit.

Post-discharge follow-up cadence:

Monitoring parameters by visit:

Counseling points:

Rehab considerations:

Ethical, Legal, and Patient Safety Considerations

— Patients presenting after intentional overdose retain decision-making capacity in most situations, but acute toxicity, altered mental status, and active suicidality may impair capacity for refusing care

— If the patient lacks capacity, emergency treatment may proceed under implied consent for life-threatening conditions

— Document capacity assessment carefully; consider psychiatry or ethics consult if refusal of medically necessary care

— Patients with active suicidal ideation or recent suicide attempt who refuse psychiatric evaluation typically meet criteria for involuntary hold (specific to state — e.g., "5150" in CA, "Section 12" in MA)

— ED physician can initiate; psychiatry evaluates within statutory time frame

— Lethal means restriction counseling with family is a Joint Commission and CDC-endorsed safety intervention — document this

— Suspected child or elder abuse (e.g., elderly patient given inappropriate polypharmacy) — report per state law

— Some states require reporting of self-harm in minors to guardians; balance with adolescent confidentiality

— Hospital-to-outpatient transition is the highest-risk period for repeat overdose

— Medication reconciliation at discharge — limit dispensed quantity to 1–2 weeks for high-risk patients

— Warm handoff to outpatient psychiatry preferred over written referral alone

— Ensure patient leaves with follow-up appointment scheduled, not just a phone number

— Drug-interaction alerts for serotonergic combinations should not be overridden without clinical justification

— Pharmacist involvement at discharge improves reconciliation accuracy

— HIPAA permits sharing information with family when patient is incapacitated and disclosure is in best interest

Step 3 management: A 22-year-old after sertraline overdose is medically stable but refuses psychiatric evaluation, stating he wants to leave. Do not discharge. Initiate an emergency psychiatric hold per state law for active suicide risk, document capacity assessment, involve psychiatry urgently, and engage family with patient permission or under implied consent if incapacitated. This sequence is exam-testable and reflects real-world standard of care.

Intentional overdose disclosure and capacity:

Involuntary psychiatric hold:

Mandatory reporting:

Transitions of care risk:

Pharmacist and EHR safety:

Confidentiality:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: If a question stem describes "shivering, tremor, ankle clonus, diaphoresis, T 39.5°C" and lists medications, scan immediately for two serotonergic agents — that's the answer regardless of what other distractors are presented.

Hunter Criteria (most sensitive ~84%, specific ~97%): serotonergic agent + clonus (spontaneous, inducible, or ocular) ± agitation, diaphoresis, tremor, hyperreflexia, or hyperthermia + hypertonia

Onset within hours — SS is fast; NMS is slow (days–weeks)

Clonus = lower extremity predominant, the most specific exam finding

Cyproheptadine is the antidote — 5-HT2A antagonist; 12 mg PO/NG load, then 2 mg q2h until response, then 8 mg q6h

Avoid antipyretics — they don't work (muscle, not hypothalamic, source)

Avoid succinylcholine in rhabdo — use rocuronium for RSI

Avoid bromocriptine, dantrolene as first-line — these are for NMS (though dantrolene has case-report use in severe refractory SS)

Avoid ondansetron for nausea — it's serotonergic and QT-prolonging

Citalopram overdose = QTc prolongation, dose-dependent

Bupropion overdose = seizures and wide QRS (NOT an SSRI but commonly co-prescribed; remember the seizure risk)

Linezolid + SSRI = classic boards trigger

Tramadol + SSRI = classic outpatient trigger

Meperidine + MAOI/SSRI = severe SS; never use meperidine in these patients

MDMA = pure serotonergic; hyperthermia is the killer

Fluoxetine washout = 5 weeks before MAOI (longest half-life of any SSRI via norfluoxetine)

All other SSRIs: 2-week washout before MAOI

Most cases resolve within 24 hours after stopping the offending agent

Mortality in severe SS: 2–12%, driven by hyperthermia complications

Sertraline is preferred SSRI in pregnancy and breastfeeding

Paroxetine is avoided in first trimester (cardiac malformations) and in elderly (anticholinergic, falls)

Fluoxetine is the only FDA-approved SSRI for children ≥8

SSRI-induced SIADH in elderly within 2–4 weeks — check sodium

SSRI bleeding risk — especially GI; consider PPI if on NSAID/aspirin

Board Question Stem Patterns

— 45-year-old on sertraline for depression presents 4 hours after starting tramadol for back pain with agitation, tremor, diaphoresis, T 38.9°C, inducible ankle clonus. Next step?

— Answer: Stop tramadol and sertraline; give IV benzodiazepines; supportive care with cooling

— 68-year-old admitted for MRSA cellulitis, on chronic fluoxetine; 36 hours after starting linezolid develops fever, hyperreflexia, lower extremity clonus, agitation.

— Answer: Stop linezolid (and fluoxetine); benzodiazepines; cyproheptadine if no improvement

— Patient on chronic paroxetine receives meperidine for postoperative shivering and develops rigidity, T 40.5°C, tachycardia. Diagnosis? Next step?

— Answer: Serotonin syndrome; stop meperidine, ICU admission, intubate with rocuronium, cooling, benzodiazepines, cyproheptadine

— 19-year-old intentional ingestion of citalopram 800 mg. ECG shows QTc 540 ms. Next step?

— Answer: Continuous cardiac monitoring, magnesium 2 g IV, correct K+ and Mg2+; ICU admission; check APAP/salicylate/pregnancy; psychiatric evaluation

— Patient on haloperidol for 1 week develops rigidity, fever, AMS, CK 25,000, hyporeflexia, no clonus.

— Answer: NMS, not SS. Treat with dantrolene, bromocriptine.

— Patient on fluoxetine being switched to phenelzine (MAOI); started phenelzine 2 weeks after stopping fluoxetine and develops SS.

— Answer: Inadequate washout — fluoxetine requires 5 weeks before MAOI

— Teen overdose on her own SSRI plus a dextromethorphan-containing cough syrup; mild SS resolves with supportive care.

— Answer: After medical clearance, psychiatric evaluation before discharge, lethal means restriction, follow-up within 1 week

— Stable post-overdose patient demands to leave AMA.

— Answer: Initiate emergency psychiatric hold, capacity assessment, do not discharge

Step 3 management: The exam loves the mechanism question: "Which of the following best explains the patient's hyperthermia?" Answer: Excessive 5-HT2A and 5-HT1A receptor stimulation leading to increased neuromuscular activity — not central thermostat reset.

Stem 1 — Classic drug-drug interaction:

Stem 2 — Linezolid trap:

Stem 3 — Postoperative meperidine:

Stem 4 — Citalopram overdose with QTc:

Stem 5 — Distinguishing SS from NMS:

Stem 6 — Antidepressant transition:

Stem 7 — Pediatric/adolescent overdose:

Stem 8 — Ethics/disposition:

One-Line Recap

Serotonin syndrome is a clinical diagnosis (Hunter criteria) of rapid-onset clonus, hyperreflexia, autonomic instability, and altered mental status occurring within hours of a serotonergic drug interaction or overdose, managed by immediate discontinuation of all serotonergic agents, aggressive benzodiazepines, active external cooling, and cyproheptadine for refractory moderate-to-severe cases.

Board pearl: When you see "ankle clonus + diaphoresis + recent medication change," the answer is serotonin syndrome — and the next step is almost always stop the drug and give benzodiazepines.

Diagnosis: Hunter criteria — serotonergic agent + clonus (spontaneous, inducible, or ocular) ± agitation, diaphoresis, tremor, hyperreflexia (lower > upper), hyperthermia. Onset within hours distinguishes from NMS (days–weeks).

First-line treatment: Stop all serotonergic drugs → IV benzodiazepines (lorazepam/diazepam, titrate, no ceiling) → active external cooling → IV crystalloid for rhabdo prevention → avoid antipyretics, restraints alone, succinylcholine, bromocriptine, dantrolene, antipsychotics.

Refractory/severe: Cyproheptadine 12 mg PO/NG load → 2 mg q2h. ICU admission for T >40°C, rigidity, AMS, hemodynamic instability. RSI with rocuronium + continuous paralysis if hyperthermia uncontrolled. Citalopram overdose adds QTc/torsades risk — magnesium, correct electrolytes.

Disposition and prevention: All intentional overdoses get APAP/salicylate/pregnancy test + psychiatric evaluation before discharge + lethal means restriction. Medication reconciliation flagging tramadol, meperidine, linezolid, ondansetron, dextromethorphan, MAOIs, triptans, St. John's wort. Honor washout periods — fluoxetine to MAOI = 5 weeks; others = 2 weeks. Sertraline is preferred SSRI in pregnancy; fluoxetine is FDA-approved for children ≥8. Follow-up with psychiatry within 1 week, primary care within 2 weeks, check sodium at 2–4 weeks for SIADH risk.